The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
Japan’s key reimbursement policy panel on October 23 gave a cold shoulder to the pharma industry’s call for giving more flexibility to the selection of comparator products in new drug pricing - a proposal towards the next pricing reform in…
To read the full story
Related Article
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
REGULATORY
- Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA
May 15, 2025
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
- Health Minister Vows Cross-Ministry Response on Trump Executive Order
May 14, 2025
- MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…